A business in context

MDCX research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-22 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-10-12 · 0001062993-26-005382 · Items 3.03,5.03,9.01

  2. 8-K · Current report

    Report date 2026-10-07 · 0001062993-26-005226 · Items 8.01,9.01

  3. 8-K · Current report

    Report date 2026-09-11 · 0001062993-26-004906 · Items 1.02,9.01

  4. 8-K · Current report

    Report date 2026-09-04 · 0001062993-26-004898 · Items 3.02,9.01

  5. 4 · Ownership change

    Report date 2026-09-04 · 0000950142-26-002522

  6. 4 · Ownership change

    Report date 2026-09-04 · 0000950142-26-002521

  7. 4 · Ownership change

    Report date 2026-09-04 · 0000950142-26-002520

  8. 4 · Ownership change

    Report date 2026-09-04 · 0000950142-26-002519

  9. 4 · Ownership change

    Report date 2026-09-04 · 0000950142-26-002518

  10. 8-K · Current report

    Report date 2026-09-02 · 0001062993-26-004806 · Items 1.01,9.01

  11. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001062993-26-004230

  12. 8-K · Current report

    Report date 2026-06-03 · 0001062993-26-003060 · Items 5.07,9.01

  13. 4 · Ownership change

    Report date 2026-06-03 · 0000950142-26-001643

  14. 4 · Ownership change

    Report date 2026-06-03 · 0000950142-26-001642

  15. 4 · Ownership change

    Report date 2026-06-03 · 0000950142-26-001641

  16. 8-K · Current report

    Report date 2026-05-20 · 0001062993-26-002900 · Items 1.01,2.03,3.01,9.01

  17. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001062993-26-002629

  18. DEF 14A · Proxy statement

    Report date 2026-06-03 · 0001062993-26-002277

  19. 10-K/A · Annual report

    Report date 2025-12-31 · 0001062993-26-002212

  20. 8-K · Current report

    Report date 2026-04-21 · 0001062993-26-002142 · Items 1.01,3.01,9.01

  21. 10-K · Annual report

    Report date 2025-12-31 · 0001062993-26-001606

  22. 8-K · Current report

    Report date 2026-03-05 · 0001062993-26-001326 · Items 3.02,9.01

  23. 8-K · Current report

    Report date 2025-12-29 · 0001062993-25-017492 · Items 1.01,9.01

  24. 8-K · Current report

    Report date 2025-12-05 · 0001062993-25-017219 · Items 1.01,3.02,7.01,9.01

  25. 8-K · Current report

    Report date 2025-11-28 · 0001062993-25-017085 · Items 5.02,7.01,9.01

  26. 8-K · Current report

    Report date 2025-11-14 · 0001062993-25-016864 · Items 8.01,9.01

  27. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001062993-25-016838

  28. 8-K · Current report

    Report date 2025-10-16 · 0001062993-25-016179 · Items 3.02,9.01

  29. 8-K · Current report

    Report date 2025-09-17 · 0001062993-25-015700 · Items 1.01,2.03,8.01,9.01

  30. 8-K · Current report

    Report date 2025-09-12 · 0001062993-25-015601 · Items 5.02

  31. 8-K · Current report

    Report date 2025-08-29 · 0001062993-25-015149 · Items 2.01,3.02,5.02,8.01,9.01

  32. 8-K · Current report

    Report date 2025-08-21 · 0001062993-25-014806 · Items 3.02,8.01,9.01

  33. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001062993-25-014058

  34. 8-K · Current report

    Report date 2025-08-04 · 0001062993-25-013468 · Items 8.01,9.01

  35. 8-K · Current report

    Report date 2025-07-29 · 0001062993-25-013266 · Items 8.01

  36. 8-K · Current report

    Report date 2025-07-22 · 0001062993-25-013073 · Items 5.07,8.01,9.01

  37. 8-K · Current report

    Report date 2025-07-14 · 0001062993-25-012767 · Items 1.01,3.02,9.01

  38. 8-K/A · Current report

    Report date 2025-06-29 · 0001062993-25-012533 · Items 9.01

  39. DEF 14A · Proxy statement

    Report date 2025-07-22 · 0001062993-25-012273

  40. 8-K · Current report

    Report date 2025-06-29 · 0001062993-25-012231 · Items 1.01,8.01,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 10 transaction rows10AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

10 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-09-04
2026-09-08
Smith Andrew AlasdairA · Grant / award
Acquired
Common Shares, no par value735294.00.17
2026-09-04
2026-09-08
Smith Andrew AlasdairA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
125000.00.0
2026-09-04
2026-09-08
Mehmud FaisalA · Grant / award
Acquired
Common Shares, no par value1470588.00.17
2026-09-04
2026-09-08
Mehmud FaisalA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
250000.00.0
2026-09-04
2026-09-08
Brennan Edward J.A · Grant / award
Acquired
Common Shares, no par value588235.00.17
2026-09-04
2026-09-08
Brennan Edward J.A · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
100000.00.0
2026-09-04
2026-09-08
Bonner Carolyn F.A · Grant / award
Acquired
Common Shares, no par value1470588.00.17
2026-09-04
2026-09-08
Bonner Carolyn F.A · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
250000.00.0
2026-09-04
2026-09-08
Bokhari RazaA · Grant / award
Acquired
Common Shares, no par value2941176.00.17
2026-09-04
2026-09-08
Bokhari RazaA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
500000.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001997296Medicus Pharma Ltd.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names

    Revenue in constant purchasing power

    USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

    No USD annual revenue periods with complete CPI coverage are available. Non-USD statements are not converted with U.S. CPI.

    Bureau of Labor Statistics · retrieved 2026-10-22 · 9 selected series; gaps remain missing

    Explore the CPI history ↗